Personalizing
Cancer Treatment for Everyone

2018 has been a revolutionary year for Massive Bio and clearly acceptance by Philips HealthWorks is an important milestone. 
 
Massive Bio was selected from the less than one dozen participants of an applicant base of over 200 start-ups to the Philips HealthWorks Startup Program running in Cambridge, MA focused on Precision Oncology. The program, which began in February and runs for 12 weeks, has us engaged in an intensive learning cycle with Philips, providing us with unparalleled access to experts from across their business. Massive Bio successfully graduated from the program in May 2018 and is currently exploring strategic collaboration opportunities with Philips. 

Massive Bio is at the fore-front of creating the science and technology to democratize access in precision oncology.

39,400 people registered to ASCO in 2018 with a common goal of expanding the reach of precision medicine.

Join Massive Bio executives and get your live demo at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Massive Bio will provide two types of demos: 
 
• Virtual tumor board powered by Massive Bio’s proprietary pathways and sub-specialists
 
• Clinical trial matching and eligibility screening platform powered by Artificial Intelligence (AI) and supervised by sub-specialists

A new high technology piece cancer fighting equipment, funded by the display of some artfully decorated bras, will be unveiled to the public this week.

Pancreatic cancer often spreads, forming metastases in the liver or lungs. The prognosis is better for patients with metastases in the lungs. However, the organ that is more likely to be affected depends on the cancer cells' ability to alter their characteristics and shape - as a research team at the Technical University of Munich (TUM) has discovered

Studying two rare inherited cancer syndromes, scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery suggests a promising strategy for treatment with drugs recently approved for other forms of cancer, said the researchers.

Researchers report that along with sharp decreases in hormone-related cancers, the risk for colorectal cancer increased by more than twofold.

Pulmonary toxicity of cancer immunotherapies has emerged as an important clinical event that requires prompt identification and management. Although often referred to as pneumonitis, pulmonary toxicity associated with immunotherapy covers a broad and overlapping spectrum of pulmonary manifestations, and, once suspected, the range of differential diagnoses of infectious and neoplastic processes might make the diagnostic process challenging for physicians.

Numerous studies have shown that miRNA levels are closely related to the survival time of patients with colon, rectal, or colorectal cancer (CRC). However, the outcomes of different investigations have been inconsistent. Accordingly, a meta-analysis was conducted to study associations among the three types of cancers.

The short perioperative period, spanning several days pre- and postsurgery, is now believed to have a nonproportionally large impact on long-term cancer outcomes (1,2). Numerous physiological responses to the newly discovered cancer and to surgical resection trigger pro-metastatic processes that can affect minimal residual disease (MRD; single tumor cells/micrometastases).

Continued evolution in cancers gives rise to intra-tumour heterogeneity (ITH), which is a major mechanism of therapeutic resistance and therefore an important clinical challenge. However, the extent, origin and drivers of ITH across cancer types are poorly understood. Here, we extensively characterise ITH across 2,778 cancer whole genome sequences from 36 cancer types.

Caregivers, cancer patients, and loved ones, you can watch this webinar about childhood cancer by  Dr. Jason Freedman, Dr. Gerald Wertheim and Dr. Sarah Tasian.

If you missed the webinar, you can still watch the recording here.

Caregivers, patients, and loved ones joined Dr. Belisario Arango and Dr. Arturo Loaiza-Bonilla on Monday, June 19, 12 pm EDT for this very informative and interactive question and answer panel format webinar. 

Our doctors answered participants questions submitted during the webinar and ones that have been sent to Massive Bio. 

Bringing state-of-the-art precision cancer care was aired Tuesday, March 14 at 12:00 EDT. 

Dr. Belisario Arango covered the following topics:

Why there is a higher cancer prevalence in patients in rural areas?
What are the challenges delivering cancer care to patients? 
Where is the future of cancer care going?

The SYNERGY-AI registry is the first of its kind to combine artificial intelligence, genomic biomarkers and multi-variate analysis to accelerate clinical trial matching and promote access to promising cancer therapies.